David-Alexandre "DA" Gros

David-Alexandre "DA" Gros is an accomplished healthcare executive and physician with extensive experience in the pharmaceutical and biotechnology industries. He currently serves as the Chief Executive Officer and Director of Eledon Pharmaceuticals, Inc., a position he has held since September 2020.1

Career Highlights

Pharmaceutical Leadership: Gros has held several high-profile positions in the pharmaceutical industry, including:

• Chief Executive Officer & Director at Eledon Pharmaceuticals, Inc. (September 2020 - Present)1
• President and Chief Operating Officer at Neurocrine Biosciences (January 2017 - December 2017)1
• Chief Business and Principal Financial Officer at Alnylam Pharmaceuticals (June 2015 - January 2017)1
• Chief Strategy Officer and EVP, Strategy & Business Development at Sanofi (August 2011 - May 2015)1

Entrepreneurship and Advisory Roles: Gros has also been involved in founding and advising several biotech companies:

• Co-Founder & Director of Eliem Therapeutics (October 2018 - October 2020)1
• Co-Founder, CEO & Chairman of Imbria Pharmaceuticals (May 2018 - September 2020)1
• Senior Advisor at Pardes Biosciences (May 2020 - August 2023)1
• Senior Executive Advisor at 4D Molecular Therapeutics (February 2018 - February 2022)1

Education

Gros has a strong educational background in both medicine and business:

• MD from The Johns Hopkins University School of Medicine (1995 - 1999)1
• MBA from Harvard Business School (2000 - 2002)1
• AB from Dartmouth College (1991 - 1995)1

Current Focus

As CEO of Eledon Pharmaceuticals, Gros is actively involved in the company's clinical trials and drug development efforts. He has expressed excitement about the company's progress, particularly with their drug tegoprubart (AT1501), which was invented at ALS TDI and is being developed for multiple indications.3

Gros is passionate about pioneering medicines, patient advocacy, and public health.4 He has also been involved in discussions about patient engagement models and patient-informed drug development.2

David-Alexandre Gros maintains an active presence on social media platforms like LinkedIn and Twitter, where he shares updates about Eledon Pharmaceuticals and discusses developments in the healthcare and pharmaceutical industries.4